Skip to main content

Table 4 Distribution of Spa types according to antibiotic non-susceptibility phenotypes for MRSA isolates (n = 1467)

From: Diversity of SCCmec elements and spa types in South African Staphylococcus aureus mecA-positive blood culture isolates

Spa type Antibiotic non-susceptibility phenotype
Azithromycin Erythromycin Clindamycin Oxacillin Cefoxitin Penicillin Trimethoprim/ Sulfamethoxazole Daptomycin Linezolid Tetracycline Rifampin Ciprofloxacin Levofloxacin Moxyfloxacin Gentamicin
t012 (n = 84) 28 (1.90%) 81 (5.52%) 71 (4.83%) 84 (5.72%) 84 (5.72%) 84 (5.72%) 11 (0.74%) 0 4 (0.27%) 14 (0.95%) 7 (0.47%) 84 (5.72%) 84 (5.72%) 83 (5.65%) 17 (1.15%)
t018 (n = 9) 4 (0.27%) 8 (0.54%) 7 (0.47%) 8 (0.54%) 9 (0.61%) 9 (0.61%) 0 0 0 1 (0.06%) 1 (0.06%) 9 (0.61%) 9 (0.61%) 9 (0.61%) 2 (0.13%)
t032 (n = 24) 4 (0.27%) 12 (0.81%) 3 (0.20) 24 (1.63%) 24 (1.63%) 24 (1.63%) 1 (0.06%) 0 0 2 (0.13%) 43 (2.93%) 23 (1.56%) 23 (1.56%) 23 (1.56%) 3 (0.20)
t037 (n = 697) 327 (22.29%) 690 (47.03%) 81 (5.52%) 693 (47.23%) 695 (47.37%) 698 (47.58%) 659 (44.92%) 5 (0.34%) 1 (0.06%) 679 (46.28%) 0 691 (47.10) 688 (46.89%) 690 (47.03%) 681 (46.42%)
t045 (n = 131) 53 (3.6%) 130 (8.86%) 13 (0.88%) 130 (8.86%) 130 (8.86%) 130 (8.86%) 11 (0.74%) 2 (0.13%) 4 (0.27%) 18 (1.22%) 6 (0.40%) 25 (1.70%) 24 (1.63%) 26 (1.77%) 123 (8.38%)
t064 (n = 49) 21 (1.43%) 29 (1.97%) 0 49 (3.34%) 49 (3.34%) 49 (3.34%) 44 (2.99%) 0 0 47 (3.20%) 47 (3.20%) 30 (2.04%) 25 (1.70_ 26 (1.77%) 47 (3.20%)
t1257 (n = 269) 79 (5.3%) 164 (11.17) 14 (0.95%) 268 (18.26%) 268 (18.26%) 268 (18.26%) 249 (16.97%) 0 2 (0.13%) 263 (17.92) 255 (17.38%) 264 (17.99%) 231 (15.74%) 231 (15.74%) 252 (17.17%)
t1443 (n = 14) 1 (0.06%) 1 (0.06%) 0 14 (0.95%) 13 (0.88%) 14 (0.95%) 13 (0.88%) 0 0 13 (0.88%) 14 (0.95%) 13 (0.88%) 13 (0.88%) 13 (0.88%) 13 (0.88%)
t1476 (n = 12) 0 5 0 12 (0.81%) 12 (0.81%) 12 (0.81%) 2 (0.13%) 0 0 9 (0.61%) 0 10 (0.68%) 7 (0.47%) 7 (0.47%) 11 (0.74%)
t1971 (n = 23) 2 (0.13%) 19 (1.29%) 1 (0.06%) 23 (1.56%) 23 (1.56%) 23 (1.56%) 23 (1.56%) 0 0 23 (1.56%) 23 (1.56%) 23 (1.56%) 21 (1.42%) 21 (1.42%) 23 (1.56%)
Novel spa types (n = 38) 9 (0.61%) 24 (1.63%) 7 (0.47%) 37 (2.52%) 37 (2.52%) 38 (2.59%) 23 (1.56%) 0 0 25 (1.70%) 16 (1.09%) 31 (2.11%) 29 (1.97%) 27 (1.84%) 27 (1.84%)
Untypeable (n = 5) 3 (0.20%) 4 (0.27%) 1 (0.06%) 5 (0.34%) 5 (0.34%) 5 (0.34%) 3 (0.20%) 0 0 3 (0.20%) 1 (0.06%) 4 (0.27%) 4 (0.27%) 3 (0.20%) 3 (0.20%)
  1. The following spa types were excluded from the table as they accounted for a small number of isolates: t008, t0121, t015, t021, t022, t0379, t059, t10304, t105, t1096, t1107, t11775, t118, t127, t13165, t1467, t148, t1555, t174, t1774, t1813, t186, t1994, t2029, t223, t2293, t230, t238, t2409, t2526, t272, t2724, t294, t304, t324, t355, t379, t421, t4268, t432, t4410, t451, t463, t4833, t4864, t498, t5483, t5691, t578, t6330, t6931, t701, t718, t729, t7962, t840, t8636, t891, t9061, t913, t932, t951
  2. Susceptibility was classified according to CLSI guidelines [26]
  3. Suggested antibiotics approved by the US Food and Drug Administration (FDA) for clinical use were included in the table. Antibiotics excluded were those that are recommended for urine only as well as those that were not tested for using the MicroScan Gram-positive PM-33 panel. In addition, vancomycin was excluded as all isolates were susceptible
  4. A total of 552 isolates were not typed